<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02430194</url>
  </required_header>
  <id_info>
    <org_study_id>EIG-300-Amendment 3</org_study_id>
    <nct_id>NCT02430194</nct_id>
  </id_info>
  <brief_title>Lonafarnib With Ritonavir in HDV (LOWR-2)</brief_title>
  <acronym>LOWR-2</acronym>
  <official_title>An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With Ritonavir-Boosting in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eiger BioPharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ankara University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eiger BioPharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-label, Dose-ranging Study to Evaluate the Safety and Efficacy of Lonafarnib With
      Ritonavir Boosting in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with
      the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major
      structural protein (HDV antigen) for replication. Up to forty-five subjects with chronic
      delta hepatitis will be randomized to receive one of nine different doses of lonafarnib.
      Dosing will occur over 12-48 weeks, and during that time, evidence of antiviral response will
      be assessed by frequent measurements of HDV-RNA. The primary therapeutic endpoint will be an
      improvement in quantitative serum HDV RNA levels after treatment with lonafarnib therapy. The
      primary safety endpoint will be the ability to tolerate the drug at the prescribed dose for
      the treatment duration. Several secondary endpoints will be measured, including side effects,
      ALT levels, and symptoms. Therapy will be stopped for intolerance to lonafarnib. This study
      is designed as a phase 2a study assessing the safety, tolerance and antiviral activity of
      nine dosing combinations of lonafarnib with ritonavir boosting with and without PEG
      IFN-alpha.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">June 15, 2017</completion_date>
  <primary_completion_date type="Actual">April 18, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decline of HDV RNA from baseline to end of treatment with lonafarnib and ritonavir</measure>
    <time_frame>12-48 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Chronic Hepatitis D Infection</condition>
  <arm_group>
    <arm_group_label>lonafarnib/ritonavir - I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 100 mg BID + ritonavir 100 mg QD;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lonafarnib/ritonavir - II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 150 mg QD + ritonavir 100 mg QD;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lonafarnib/ritonavir - III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 75 mg BID + ritonavir 100 mg BID; + PEG IFN-a 180 ug QW on Week 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lonafarnib/ritonavir - IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 50 mg BID + ritonavir 100 mg BID; + PEG IFN-a 180 ug QW on Week 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lonafarnib/ritonavir - V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 100 mg BID + ritonavir 50 mg BID;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lonafarnib/ritonavir - VI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 100 mg QD + ritonavir 100 mg QD;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lonafarnib/ritonavir - VII</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 50 mg BID + ritonavir 100 mg BID; + PEG IFN-a 180 ug QW;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lonafarnib/ritonavir/PEG IFN-a - VIII</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 25 mg BID + ritonavir 100 mg BID + PEG IFN-a 180 ug QW;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lonafarnib/ritonavir/PEG IFN-a - IX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 50 mg BID + ritonavir 100 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lonafarnib/ritonavir - X</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 25 mg BID + ritonavir 100 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lonafarnib</intervention_name>
    <description>antiviral farnesyl transferase inhibitor</description>
    <arm_group_label>lonafarnib/ritonavir - I</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - II</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - III</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - IV</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - V</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - VI</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - VII</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir/PEG IFN-a - VIII</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir/PEG IFN-a - IX</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - X</arm_group_label>
    <other_name>Sarasar, EBP994</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>CYP 3A4 inhibitor, lonafarnib booster</description>
    <arm_group_label>lonafarnib/ritonavir - I</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - II</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - III</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - IV</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - V</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - VI</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - VII</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir/PEG IFN-a - VIII</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir/PEG IFN-a - IX</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - X</arm_group_label>
    <other_name>Norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG IFN-a</intervention_name>
    <description>immunomodulator</description>
    <arm_group_label>lonafarnib/ritonavir - III</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - IV</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - VII</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir/PEG IFN-a - VIII</arm_group_label>
    <other_name>Pegasys</other_name>
    <other_name>PEG IFN-alpha</other_name>
    <other_name>Pegylated interferon-alpha-2a</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females, 18 to 65 years of age who are diagnosed with HDV by PCR

          -  Chronic hepatitis D infection, genotype 1, documented by a positive anti-HDV Ab test
             at least of 6 months duration and detectable HDV RNA by PCR within 3 months to study
             entry

          -  Liver biopsy within the last two years (biopsy can be done at the Screening Visit)

          -  Positive viral load of &gt;100,000 copies/mL as measured by quantitative PCR

          -  Electrocardiogram (ECG) shows no acute ischemia or clinically significant abnormality
             and a QT/QTc interval &lt;450 milliseconds - using Bazett's correction

          -  Females of childbearing potential (intact uterus and within 1 year since the last
             menstrual period) should be non-lactating and have a negative serum pregnancy test. In
             addition, these subjects should agree to use one of the following acceptable birth
             control methods throughout the study:

               1. abstinence

               2. surgical sterilization (bilateral tubal ligation, hysterectomy, bilateral
                  oophorectomy) six months minimum

               3. IUD in place for at least six months

               4. barrier methods (condom or diaphragm) with spermicide

               5. surgical sterilization of the partner (vasectomy for six months)

               6. hormonal contraceptives for at least three months prior to the first dose of
                  study drug

          -  Willing and able to comply with study procedures and provide written informed consent

        Exclusion Criteria:

          -  Participation in a clinical trial with or use of any investigational agent within 30
             days of Study Visit 1

          -  Patients co-infected with HIV

          -  Patients with screening tests positive for HCV, or anti-HIV Ab

          -  History of decompensated cirrhosis within the past year

          -  Active jaundice defined by total bilirubin &gt; 2.0 excluding Gilbert's disease

          -  INR ≥ 1.5

          -  Eating disorder or alcohol abuse within the past 2 years, excessive alcohol intake (&gt;
             20 g per day for females (1.5 standard alcohol drinks) or &gt; 30 g per day for males
             (2.0 standard alcohol drinks) (a standard drink contains 14 g of alcohol: 12 oz of
             beer, 5 oz of wine or 1.5 oz of spirits) (1.0 fluid oz (US) = 29.57 mL)

          -  Drug abuse within the last six months with the exception of cannabinoids and their
             derivatives

          -  Patients with absolute neutrophil count (ANC) &lt; 1500 cells/mm3; platelet count &lt;
             100,000 cells/mm3; hemoglobin &lt; 12 g/dL for women and &lt; 13 g/dL for men; abnormal
             TSH,T4, or T3 or thyroid function not adequately controlled; or serum creatinine
             concentration ≥ 1.5 times upper limit of normal (ULN)

          -  History or clinical evidence of any of the following:

               1. variceal bleeding, ascites, hepatic encephalopathy, CTP score &gt; 6, decompensated
                  liver disease or any other form of non-viral hepatitis

               2. immunologically mediated disease (e.g., rheumatoid arthritis, inflammatory bowel
                  disease, severe psoriasis, systemic lupus erythematosus) requiring more than
                  intermittent nonsteroidal anti-inflammatory medications for management or that
                  requires frequent or prolonged use of corticosteroids (inhaled asthma medications
                  are allowed)

               3. any malignancy within 3 years except for basal cell skin cancer

               4. significant or unstable cardiac disease (e.g., angina, congestive heart failure,
                  uncontrolled hypertension, history of arrhythmia)

               5. chronic pulmonary disease (e.g., chronic obstructive pulmonary disease)
                  associated with functional impairment

               6. severe or uncontrolled psychiatric disease, including severe depression, history
                  of suicidal ideation, suicidal attempts or psychosis requiring medication and/or
                  hospitalization 2

          -  Patients with a body mass index &gt; 30 kg/m2

          -  Concomitant drugs known to prolong the QT interval
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cihan Yurdaydin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ankara University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ankara University Medical School</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://eigerbio.com</url>
    <description>Eiger BioPharmaceuticals company website</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>April 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2015</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis D</mesh_term>
    <mesh_term>Hepatitis D, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Lonafarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

